Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial

Abayomi et al., Trials, doi:10.1186/s13063-021-05675-x, LACCTT, PACTR202004801273802
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Estimated 800 patient HCQ early treatment RCT with results not reported over 2 years after estimated completion. Registry updates indicate recruiting started in June 2020 with estimated completion in December 2020. In August 2021 the registry was updated to indicate the trial had been "stopped early/terminated".
39 HCQ RCTs have results missing long after expected Abayomi, Abu-Helalah, Ajili, Akram, Al Ansari, Aston, Borrie, Burney, Butler, Chauffe, Connor, El-Sherbiny, Farooq, Gagneux-Brunon, Genton, Ghanem-Zoubi, González, Granados-Montiel, Gül, Hawari, James, Kara, Kim, Levi, Mežnar, Moraes, Morales-Asencio, Mordmüller, Nanni, Niriella, Okasha, Pellegrini, Pineda, Sarwar, Sarwar (B), Sow, Treluyer, WellStar, White
The trials report a total of 25,949 patients, with 13 trials having actual enrollment of 8,689, and the remainder estimated.
Abayomi et al., 4 Dec 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Nigeria, peer-reviewed, trial PACTR202004801273802 (LACCTT). Contact: sea.anya@gmail.com (corresponding author), olusegun.ogboye@lagosstate.gov.ng.
This PaperHCQAll
A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial
A Abayomi, A Osibogun, O Ezechi, K Wright, B Ola, O Ojo, Y Kuyinu, E Zamba, H Abdur-Razzaq, O A Erinoso, S E Anya
Trials, doi:10.1186/s13063-021-05675-x
Background: The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first identified in Wuhan, Hubei, China, in December 2019. It was recognized as a pandemic by the World Health Organization on 11 March 2020. Outbreak forecasting and mathematical modelling suggest that these numbers will continue to rise. Early identification of effective remedies that can shorten the duration and severity of illness is critical for Lagos State, which is the epi-centre of the disease in Nigeria. Methods: This is a multi-centre, randomized, double-blind placebo-controlled superiority trial. The study investigates the efficacy of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir added on to standard of care compared to standard of care only in patients with COVID-19 disease. The primary outcome is the clinical status of patients measured using a 7-point ordinal scale at day 15. Research participants and clinicians will be blinded to the allocated intervention. Outcome measures will be directly assessed by clinicians. Statistical analysis will be done by a team blinded to the identity and allocation of research participants. Data analysis will follow intention-to-treat methods, using R software. Discussion: The current study is of strategic importance for Lagos State in potentially curbing the health, social and economic burden of COVID-19 disease. Should the current study demonstrate that either of the three intervention drugs is more efficacious than standard therapy alone, the State Ministry of Health will develop an evidence-based guideline for the management of COVID-19 in Lagos State. The findings will also be shared nationally and with other states which may lead to a standardized national guideline for the treatment of COVID-19 in Nigeria.
Supplementary Information The online version contains supplementary material available at https://doi. org/10.1186/s13063-021-05675-x. Additional file 1. Research Consent form. Additional file 2. Case Reporting Forms. Additional file 3. DSMB Charter. Authors' contributions {31b} All authors contributed to the design of the study and approved the final version. AO, KW, BO, EZ, OAE and SEA conceived the study; AS, OE, KW and YK led on ethics, monitoring and regulatory compliance; OO contributed to the selection of doses of chloroquine and hydroxychloroquine as well as the unblinding protocol; HA, OAE and SEA led on the study design; HA, OAE and SEA prepared the protocol. Funding {4} The Lagos State Government will provide funding for this trial. The funding body had no role in the design of the study, data collection, analysis and interpretation of data and in writing the manuscript. Declarations Ethics approval and consent to participate {24} This trial received ethical approval from the Lagos State Health Research Ethics Committee on April 7, 2020, with reference number LREC/06/10/1344. The trial also received regulatory approval from the National Agency for Food and Drug Administration and Control on May 12, 2020, with reference number NAFDAC/DER/SW/CT&D//2020/VOL.1. Participants will be provided with essential information about the trial and invited to sign an informed consent document. Consent for publication {32} Written informed consent for publication will..
References
Barnard, Hubbard, Burton, Smee, Morrey et al., Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine, Antivir Chem Chemother, doi:10.1177/095632020401500102
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavirritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Chan, Chan, Kao, To, Zheng et al., Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus, J Infect, doi:10.1016/j.jinf.2013.09.029
Chan, Lai, Chu, Tsui, Tam et al., Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study, Hong Kong Med J Xianggang Yi Xue Za Zhi
Chen, Chan, Jiang, Kao, Lu et al., In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds, J Clin Virol, doi:10.1016/j.jcv.2004.03.003
Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)
Cheng, Cheng, Chen, Lin, Chuang et al., Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus, Antivir Res, doi:10.1016/j.antiviral.2014.12.011
Chu, Cheng, Hung, Wong, Chan et al., Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax, doi:10.1136/thorax.2003.012658
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Gautret, Lagier, Parola, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study
Gorbalenya, Baker, Baric, De Groot, Drosten et al., The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat Microbiol, doi:10.1038/s41564-020-0695-z
Groneberg, Poutanen, Low, Lode, Welte et al., Treatment and vaccines for severe acute respiratory syndrome, Lancet Infect Dis, doi:10.1016/S1473-3099(05)70022-0
Hopkins, Coronavirus COVID-19 global cases
Hu, Frieman, Insights from nanomedicine into chloroquine efficacy against COVID-19, Nat Nanotechnol, doi:10.1038/s41565-020-0674-9
Jie, He, Xi, Zhi, Jiehe et al., Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia, Zazhi Chin J Tuberc Respir Dis
Keyaerts, Vijgen, Maes, Neyts, Van Ranst, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem Biophys Res Commun, doi:10.1016/j.bbrc.2004.08.085
Loutfy, Blatt, Siminovitch, Ward, Wolff et al., Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study, JAMA, doi:10.1001/jama.290.24.3222
Mackenzie, Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials, Am J Med, doi:10.1016/0002-9343(83)91269-X
Mair-Jenkins, Saavedra-Campos, Baillie, Cleary, Khaw et al., The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, J Infect Dis, doi:10.1093/infdis/jiu396
Naarding, Baan, Pollakis, Paxton, Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes, Retrovirology, doi:10.1186/1742-4690-4-6
Nicastri, Petrosillo, Bartoli, Lepore, Mondi et al., IRCCS. Recommendations for COVID-19 clinical management, Infect Dis Rep
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis, doi:10.1016/S1473-3099(03)00806-5
Soto, Nigeria has chloroquine poisonings after Trump praised drug, Bloomberg
Tan, Ooi, Lin, Tan, Ling et al., Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs, Emerg Infect Dis, doi:10.3201/eid1004.030458
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, doi:10.1186/1743-422X-2-69
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Sun, Wu, Xu, Pan et al., Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis, J Virol, doi:10.1128/JVI.00948-15
Who Director, General's opening remarks at the media briefing on COVID-19
Wu, Leung, Leung, Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study, Lancet Lond Engl
Wu, Ma, Kuo, Juan, Cheng, Small molecules targeting severe acute respiratory syndrome human coronavirus, Proc Natl Acad Sci U S A, doi:10.1073/pnas.0403596101
Yamamoto, Yang, Yoshinaka, Amari, Nakano et al., HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus, Biochem Biophys Res Commun, doi:10.1016/j.bbrc.2004.04.083
Yan, Zou, Sun, Li, Xu et al., Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model, Cell Res, doi:10.1038/cr.2012.165
Zhang, Liu, Tan, Huang, Dong et al., Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection, Chest, doi:10.1016/j.chest.2020.03.039
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit